Identification and Validation of Molecular Markers in Lung Cancer
- To identify new molecular abnormalities specific to the development of squamous cell
carcinoma of the lung.
- To determine the prevalence of candidate biomarkers in lung cancer progression.
- To determine the odds of developing lung cancer according to biomarker status in
- To determine the odds of developing lung cancer according to proteomic biomarker status
in the normal bronchial epithelium of high-risk patients.
OUTLINE: This is a multicenter study.
Tissue samples are collected at the time of fluorescence bronchoscopy for laboratory
biomarker studies. Blood, sputum, and urine samples are also collected. Gene and protein
expression studies are performed on the samples using comparative genomic hybridization
array, 3q oligonucleotide microarray, matrix-assisted laser desorption/ionization time of
flight mass spectrometry (MALDI-TOF), fluorescence in situ hybridization (FISH), and
Patients' medical records are reviewed to collect information about the patient's past
medical history and pertinent laboratory and radiography results.
Patients and healthy volunteers are followed annually via telephone or a mailed
Identification of new molecular markers specific to the development of squamous cell lung cancer
Pierre P. Massion, MD
Vanderbilt-Ingram Cancer Center
|Vanderbilt-Ingram Cancer Center||Nashville, Tennessee 37232-6838|
|Veterans Affairs Medical Center - Nashville||Nashville, Tennessee 37212|
|Vanderbilt-Ingram Cancer Center - Cool Springs||Nashville, Tennessee 37064|
|Vanderbilt-Ingram Cancer Center at Franklin||Nashville, Tennessee 37064|